Additional file 6: Table S3. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
收藏数据链接：
官方服务：
资源简介：
Anti-GAB2 IP of Axitinib vs DMSO treated cells. SILAC ratios are normalized to GAB2 and log2 transformed. Significant affected proteins are determined using Significance A (MaxQuant, p
提供机构：
Zehan Hu创建时间：
2016-12-15
